Literature DB >> 15692760

Hazard rates of recurrence following diagnosis of primary breast cancer.

Ismail Jatoi1, Anna Tsimelzon, Heidi Weiss, Gary M Clark, Susan G Hilsenbeck.   

Abstract

We calculated hazard rates for recurrence in patients with primary breast cancer (stage I, II; no adjuvant therapy). Previous publications have indicated a peak in hazard rates for recurrence (or death) at approximately 2-3 years after diagnosis of primary breast cancer. However, there have been conflicting reports concerning the presence of a second peak at 5-7 years after diagnosis. In this study, we estimated hazard functions by the Nelson-Aalen method and fit by cubic-linear and cubic-cubic-linear models to test for the presence of one or two peaks, respectively. We identified two peaks in hazard of recurrence, one at 2 years and another at 5 years. The 5-year peak, though statistically significant, represents very small differences in patient outcome. This additional peak may be an artifact of interval censoring due to a tendency to follow-up patients at specific bench-mark time points.

Entities:  

Mesh:

Year:  2005        PMID: 15692760     DOI: 10.1007/s10549-004-1722-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  22 in total

1.  Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.

Authors:  Claudine Isaacs; Pia Herbolsheimer; Minetta C Liu; Mary Wilkinson; Yvonne Ottaviano; Gina G Chung; Robert Warren; Jennifer Eng-Wong; Philip Cohen; Karen L Smith; Karen Creswell; Antonella Novielli; Rebecca Slack
Journal:  Breast Cancer Res Treat       Date:  2010-10-26       Impact factor: 4.872

2.  Breast cancer adjuvant therapy: time to consider its time-dependent effects.

Authors:  Ismail Jatoi; William F Anderson; Jong-Hyeon Jeong; Carol K Redmond
Journal:  J Clin Oncol       Date:  2011-05-09       Impact factor: 44.544

3.  Time-Varying Effects of Breast Cancer Adjuvant Systemic Therapy.

Authors:  Ismail Jatoi; Hanna Bandos; Jong-Hyeon Jeong; William F Anderson; Edward H Romond; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2015-10-30       Impact factor: 13.506

Review 4.  Long-term Consequences of the Acute Neural-Inflammatory Stress Response in the Cancer Surgical Patient: New Findings and Perspectives.

Authors:  Bernhard Riedel; Erica Sloan; Patrice Forget
Journal:  Int Anesthesiol Clin       Date:  2016

5.  Breast and colorectal cancer recurrence and progression captured by five U.S. population-based registries: Findings from National Program of Cancer Registries patient-centered outcome research.

Authors:  Trevor D Thompson; Lori A Pollack; Christopher J Johnson; Xiao-Cheng Wu; Judy R Rees; Mei-Chin Hsieh; Randi Rycroft; MaryBeth Culp; Reda Wilson; Manxia Wu; Kevin Zhang; Vicki Benard
Journal:  Cancer Epidemiol       Date:  2020-01-06       Impact factor: 2.984

Review 6.  Perspectives in anaesthesia for cancer surgery.

Authors:  Patrice Forget; Marc De Kock
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-28       Impact factor: 4.553

7.  Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC).

Authors:  Dorit Di Gioia; Volker Heinemann; Dorothea Nagel; Michael Untch; Steffen Kahlert; Ingo Bauerfeind; Thomas Koehnke; Petra Stieber
Journal:  Tumour Biol       Date:  2011-05-08

Review 8.  Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?

Authors:  Olga A Martin; Robin L Anderson; Kailash Narayan; Michael P MacManus
Journal:  Nat Rev Clin Oncol       Date:  2016-08-23       Impact factor: 66.675

9.  The effect of local therapy on breast cancer mortality: is there an age-interaction?

Authors:  Ismail Jatoi
Journal:  Indian J Surg Oncol       Date:  2013-11-05

10.  New concepts in breast cancer emerge from analyzing clinical data using numerical algorithms.

Authors:  Michael Retsky
Journal:  Int J Environ Res Public Health       Date:  2009-01-20       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.